Zacks Investment Research downgraded Teladoc Inc (NYSE:TDOC) to Sell in a report released today.
- Updated: September 20, 2016
Zacks Investment Research has downgraded Teladoc Inc(NYSE:TDOC) to Sell in a report released on Tuesday September 20 2016.
On 8/04/2016, Deutsche Bank released a statement for Teladoc Inc(NYSE:TDOC) lowered the target price from $21.00 to $20.00 that indicated a possible upside of 0.33%.
Yesterday Teladoc Inc (NYSE:TDOC) traded 1.24% lower at $18.81. Teladoc Inc’s 50-day average is $17.90 and its two hundred day average is $13.87. With the last stock close up 34.55% relative to the 200-day average, compared to the S&P 500 Index which has fallen -0.01% over the date range. 283,039 shares of TDOC exchanged hands, down from ann avg. volume of 661,308.
Recent Performance Graphic:
Teladoc Inc has a 52 week low of $9.08 and a 52 week high of $24.69 and has a total market value of $0.0.
General Information About Teladoc Inc (NYSE:TDOC)
Teladoc, Inc., together with its subsidiaries, is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company operates through health services segment. Its solution connects its Members, with its over 3, 000 board-certified physicians and behavioral health professionals who treat a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation. Its enterprise scale platform is offered for real-time sharing of clinical and non-clinical data in real time among the Teladoc constituents, which include Members, Providers, physician network operations center staff, nurses, SureScripts for electronic medication prescription writing, routing and fulfillment and health plans for claims processing, and clinical summaries and clinical alerts.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.